Mesenchymal stromal cells but not cardiac fibroblasts exert beneficial systemic immunomodulatory effects in experimental myocarditis.

Systemic application of mesenchymal stromal cells (MSCs) in inflammatory cardiomyopathy exerts cardiobeneficial effects. The mode of action is unclear since a sufficient and long-acting cardiac homing of MSCs is unlikely. We therefore investigated the regulation of the immune response in coxsackievi...

Whakaahuatanga katoa

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	Konstantinos Savvatis, Sophie van Linthout, Kapka Miteva, Kathleen Pappritz, Dirk Westermann, Joerg C Schefold, Gerhard Fusch, Alice Weithäuser, Ursula Rauch, Peter-Moritz Becher, Karin Klingel, Jochen Ringe, Andreas Kurtz, Heinz-Peter Schultheiss, Carsten Tschöpe
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Public Library of Science (PLoS) 2012-01-01
Rangatū:	PLoS ONE
Urunga tuihono:	https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22815907/pdf/?tool=EBI
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Mesenchymal stromal cells but not cardiac fibroblasts exert beneficial systemic immunomodulatory effects in experimental myocarditis.

Ngā tūemi rite